Cytokinetics reports Q3 2026 results with higher revenue and reduced loss
+1 new source since this summary was written
Cytokinetics Inc. posted third‑quarter 2026 revenue of $47.6 million, driven mainly by $44.5 million of MYQORZO sales. The company recorded a net loss of $190.1 million, or $1.37 per share, an improvement from the prior‑year loss of $306.2 million, or $2.55 per share. Over 2,800 patients received MYQORZO by September 30, and the firm plans to file a supplemental NDA for aficamten in non‑obstructive HCM in Q4 2026 and a European submission in early 2027. Cash and investments stood at about $1.6 billion, down from $1.7 billion at the end of Q2.
Why it matters
The higher revenue and narrower loss indicate that MYQORZO’s launch momentum is translating into stronger cash flow, which may support continued R&D spending and upcoming regulatory filings. Investors should note the reduced cash balance of $1.6 billion, which could affect liquidity planning for the remainder of 2026.
Key facts
- 1Third‑quarter 2026 revenue was $47.6 million, up from $1.9 million in the same quarter of 2025. stocktitan.net
- 2MYQORZO generated $44.5 million of net product revenue in Q3 2026. stocktitan.net
- 3Net loss for the quarter was $190.1 million, or $1.37 per share. finance.yahoo.com
- 4Over 2,800 patients had been dispensed MYQORZO by September 30, 2026. stocktitan.net
- 5The company plans to submit a supplemental NDA for aficamten in non‑obstructive HCM in Q4 2026 and a Type II variation in the EU in early 2027. stocktitan.net
- 6Cash, cash equivalents and investments were approximately $1.6 billion at September 30, 2026, compared with $1.7 billion at June 30, 2026. stocktitan.net
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.